keyboard_arrow_up

Treating Refractory Hematological Malignancies - Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics

Reportstack has announced a new market research publication on Treating Refractory Hematological Malignancies - Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics. Targeting unmet needs in the treatment of cancer through innovative drug development strategies have witnessed favorable outcomes recently.  New targets have been validated in this process where kinases lead the way.  Approval of Kyprolis (carfilzomib, Onyx), Pomalyst (pomalidomide, Celgene) for the Relapsed and Refractory Multiple Myeloma (RRMM) and their successful commercial launch validate the strategy deployed by the companies.  We expect a similar scenario to unfold in the treatment of recurrent/ refractory MDS (RR-MDS, High-Risk MDS), and AML (relapsed/ refractory AML, R/R AML).  Innovative approach to treating unmet need has been handsomely rewarded in the past through in-licensing or outright acquisition of the mature/nascent product/innovator company at a premium.  The successful IPOs’ of Ambit and Onconova are indicators of the optimism prevailing amongst the investors, Patients and Physicians community.
The report provides an overview of the approved therapies for AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory pts.  The report highlights the competition and commercial opportunity in pursuing this therapy area – Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them.  Key M&A activities that have taken place in this area in the last 5 years and a list of products in early /late stages of development available for in-licensing are highlighted in the report.

Key Points Discussed in the Report –
Overview of the disease and Unmet need
Drugs in the pipeline – Mechanism of Action (MoA) and Clinical Stage of development
Myelodysplastic Syndromes –  Lower-risk, Higher-risk, and recurrent / refractory MDS
Acute Myeloid Leukemia – Untreated/ newly diagnosed and relapsed / refractory AML
Key milestones
Launch Timeline and Commercial Opportunity of Late-stage pipeline (RR MDS and RR AML)
M&A and Licensing deals in the last 5 years
In-licensing and/or M&A Opportunity
Detailed Company analysis includes Clinical data of drugs , Milestones, and Valuation
Ambit Biosciences (AMBI)
Onconova Therapeutics (ONTX)

To view the table of contents and know more details please visit Treating Refractory Hematological Malignancies - Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics report.